A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: Modified randomized exposure controlled trial (mRECT)

Stroke

Volumn 40, Issue 11, 2009, Pages 3518-3525

  Teal, Philip ^a   Davis, Stephen ^b   Hacke, Werner ^c   Kaste, Markku ^d   Lyden, Patrick D ^e   Fierus, Monika ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BAYER PHARMA AG   (Germany)

Author keywords

Acute stroke; Neuroprotective agents; Repinotan; Stroke recovery; Thrombolysis

Indexed keywords

PLACEBO; REPINOTAN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AGITATION; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFUSION RATE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; BENZOPYRANS; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERNATIONALITY; MALE; MIDDLE AGED; STROKE; THIAZOLES;

EID: 70350534678     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.551382     Document Type: Article

References (8)

1. Mauler F, Horvath E. Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury. J Cereb Blood Flow Metab. 2005;25:451-459.
2. Heinig R, Böttcher MF. Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers. Clin Drug Investig. 2005;25: 115-123.
3. Heinig R, Sundaresan P, Shah A, Boettcher MF. Effect of gender and age on the pharmacokinetics of repinotan. Clin Drug Investig. 2005;25: 125-134.
4. Tanigawa T, Heinig R, Kuroki Y, Higuchi S. Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach. Drug Metab Pharmacokinet. 2006;21:61-69.
5. Teal P, Silver FL, Simard D. The BRAINS study: safety, tolerability, and dose-finding of repinotan in acute stroke. Can J Neurol Sci. 2005 Feb;32: 61-67.
6. Teal P, Lyden P, Hennerici M, Kaste M, Davis SM, Sprenger K. Design and rationale for the modification of a randomized exposure control trial of repinotan in acute ischemic stroke [Abstract]. Stroke. 2003;34:285.
7. Beal SL, Sheiner LB. NONMEM Users Guide, NONMEM Project Groups. San Francisco: University of California; 1992.
8. Bayer Inc. BAY x3702 (Repinotan HCl) Investigator's Brochure. Leverkusen, Germany: Bayer; November 3, 2003.